Reading ZVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZVRA free→Reading ZVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZVRA free→QuarterlyIQ Insights · ZVRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 6, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2026, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, May 6, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.1…
Entry into a Material Definitive Agreement. On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Colla…
Termination of a Material Definitive Agreement. On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”). The Credit Agreement provided for a senior secured loan facility in an aggregate prin…
Results of Operations and Financial Condition. On March 9, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the fourth quarter ended December 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Monday, March 9, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026. On March 5, 2026, the Company issued a press release announcing the appointment of Mr. Renz as Chief Financial Officer, a copy of which is attached hereto as Exhibit 99.…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026. Mr. Sangiovanni has served…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On November 26, 2025, Wendy Dixon notified the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) that she was resigning from the Board and each committee of the Board on which she served, subject to the Board’s acceptance. On November 27, 2025, the Board accepted her resignation effective as of December 2, 2025. Dr. D…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “Separation Date”), in order to pursue other professional opportunities. In connection with…
Results of Operations and Financial Condition. On November 5, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the third quarter ended September 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, November 5, 2025, at 4:30 p.m. ET. A copy of the press release is furnished a…
Results of Operations and Financial Condition. On August 12, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 12, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibi…
Results of Operations and Financial Condition . On May 13, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, May 13, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.…
Results of Operations and Financial Condition. On April 7, 2025, the Company issued a press release in relation to the Asset Sale, in which the Company announced that as of March 31, 2025, the Company’s cash, cash equivalents and investments were approximately $68.7 million. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in this item, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section…
Other Events. As noted above, on April 7, 2025, the Company announced that as of March 31, 2025, the Company’s cash, cash equivalents and investments were approximately $68.7 million. The foregoing cash, cash equivalents and investments information provided in this Current Report on Form 8-K is based on preliminary unaudited information and management estimates for the quarter ended March 31, 2025, is not a comprehensive statement of the Company’s financial results as of and for the fiscal qu…
Completion of Acquisition or Disposition of Assets. On April 1, 2025, Zevra Therapeutics, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when MIPLYFFA (arimoclomol) was ap…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.